New injection aims to tame lupus when standard treatments fail
NCT ID NCT06530849
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an injection called GC012F in 20 adults with refractory systemic lupus erythematosus (SLE) — a type of lupus that hasn't responded to standard treatments. The goal is to see if the therapy is safe and can reduce disease activity. Participants receive a single infusion and are monitored for side effects and lupus control over 48 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Shanghai, China
-
Research Site
Wuhan, 430060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune cell shot aims to tame tough lupus cases
- Lupus patients get hope from Cancer-Fighting cell therapy
- Lupus patients may get new hope from In-Body cell therapy
- Immune cell therapy shows promise for Tough-to-Treat lupus
- Could CAR T-Cells tame tough lupus? tiny trial aims to find out
- Immune cell therapy shows promise for tough lupus cases